ADGRA2 and lung adenocarcinoma: Notably, disrupting this GPR124-mediated activation mechanism—either by silencing GPR124 and Wnt7b or using a potent Wnt/β-catenin-specific small-molecule signaling inhibitor—led to a significant reduction in brain metastases of lung adenocarcinoma cells [112].